Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.40 |
| ▸ | HTT | P42858 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880053 | 1.00 | EGFR (0.41) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL31662896 | 0.74 | L3MBTL1 (0.45) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL29427603 | 0.74 | PI4KA (0.52) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL29427596 | 0.74 | PI4KA (0.52) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL2041433 | 0.74 | PI4KA (0.52) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL1065478 | 0.74 | PDE4A (0.52) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL6837820 | 0.74 | EGFR (0.41) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL30831937 | 0.74 | PDE4A (0.52) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL12559949 | 0.74 | EGFR (0.41) | EGFRKDM4EHSP90AA1HTTLMNA | |
| SCHEMBL29416394 | 0.74 | PDE4A (0.52) | EGFRKDM4EHSP90AA1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| EP-3630759-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | Centre National De La Recherche Scientifique (FR) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215557-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-11-29 | — | — | WO | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-0802914-B1 | ARYL- AND HETEROARYL- PURINE AND PYRIDOPYRIMIDINE DERIVATIVES | PHARMACIA & UPJOHN SPA (IT) | 2001-06-06 | — | — | EP | disclosed |
| EP-0595467-B1 | Process for preparing antifolate 4-hydroxypyrrolo 2,3-d pyrimidine derivatives | LILLY CO ELI (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1018514-A1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2000-07-12 | — | — | EP | disclosed |
| US-5965563-A | NOVEL PURINE DERIVATIVES SUCH AS N6-(2-OXINDOL-5-YL) ADENINE, METHODS OF SYNTHESIZING THEM; USE AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-10-12 | — | — | US | disclosed |
| EP-0802914-A1 | ARYL AND HETEROARYL PURINE COMPOUNDS | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-10-29 | — | — | EP | disclosed |
| WO-1997018212-A1 | ARYL AND HETEROARYL PURINE COMPOUNDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-05-22 | — | — | WO | disclosed |
| EP-0595467-A2 | Process for preparing antifolate 4-hydroxypyrrolo 2,3-d pyrimidine derivatives | ELI LILLY AND COMPANY (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5278307-A | Process for preparing 4-hydroxypyrrolo(2,3-d)pyrimidine based antifolate compounds and intermediates | ELI LILLY AND COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| US-5223503-A | Antitumor, anticarcinogenic agents | ELI LILLY AND COMPANY (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0511792-A2 | Pyridoprimidine derivatives as antineoplastic agents | ELI LILLY AND COMPANY (US) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | EGFR 305/4885KDM4E 3118/4885HSP90AA1 879/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | EGFR 187/4885KDM4E 2590/4885HSP90AA1 2085/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | EGFR 187/4885KDM4E 2590/4885HSP90AA1 2085/4885 |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | EGFR 1611/4885KDM4E 3807/4885HSP90AA1 2731/4885 |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CACNA1E, KCNA1, KCNT1 | EGFR 305/4885KDM4E 3118/4885HSP90AA1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.